Galectin Therapeutics

11 employees • United States

Company Overview

Company Name

Galectin Therapeutics

Address

United States

Employees

11

About Galectin Therapeutics

Galectin Therapeutics is a US-based company with approximately 11 employees. The company is focused on developing proprietary galectin inhibitors and discovering new treatments for diseases such as non-alcoholic steatohepatitis (NASH) cirrhosis, fibrosis, and cancer. Their lead drug candidate, belapectin, is currently in clinical trials for NASH cirrhosis.

Frequently Asked Questions about Galectin Therapeutics

Technologies Used

Social Profiles

Key Decision Makers

Harold Shlevin Director Board of Directors
LinkedIn
Jennifer Louris Manager Clinical Operations
LinkedIn